SCHEMBL15909030

SCHEMBL15909030

N#Cc1c(Br)c(Br)cc2c1Nc1ccccc1S2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX1 Q9Y5S8 8/20 0.44
MAPT P10636 5/20 0.44
GAA P10253 4/20 0.44
BCHE P06276 2/20 0.44
ACHE P22303 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
CYP1A2 P05177 1/20 0.44
POLB P06746 1/20 0.44
CYP3A4 P08684 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
ALOX15 P16050 1/20 0.44
ALOX12 P18054 1/20 0.44
MAOA P21397 1/20 0.44
CNR1 P21554 1/20 0.44
PTGS1 P23219 1/20 0.44
SLC6A2 P23975 1/20 0.44
HTR2C P28335 1/20 0.44
PTGS2 P35354 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15909029 0.78 NOX1 (0.46) NOX1MAPTGAABCHEACHE
SCHEMBL6545376 0.71 GAA (0.44) NOX1MAPTGAABCHEACHE
SCHEMBL31730317 0.70 NOX1 (0.48) NOX1MAPTGAABCHEACHE
SCHEMBL6206910 0.70 MAPT (0.43) NOX1MAPTGAABCHEACHE
SCHEMBL5510891 0.70 NOX1 (0.55) NOX1MAPTGAABCHEACHE
SCHEMBL31042995 0.70 NOX1 (0.59) NOX1MAPTGAABCHEACHE
SCHEMBL4534080 0.70 NOX1 (0.59) NOX1MAPTGAABCHEACHE
SCHEMBL2583563 0.69 NOX1 (0.53) NOX1MAPTGAABCHEACHE
SCHEMBL11448015 0.69 GAA (0.41) NOX1MAPTGAABCHEACHE
SCHEMBL12003864 0.68 NOX1 (0.57) NOX1MAPTGAABCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170151253-A1 Compounds, Compositions, and Methods for Treating Alzheimer's Disease Prosetta Antiviral, Inc. 2017-06-01 US disclosed
US-9382221-B2 Compounds, compositions, and methods for treating alzheimer's disease PROSETTA ANTIVIRAL INC. (US) 2016-07-05 US disclosed
US-20140315897-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ALZHEIMER'S DISEASE Prosetta Antiviral, Inc. 2014-10-23 US disclosed
US-8796448-B1 Compounds, compositions, and methods for treating Alzheimer's disease PROSETTA ANTIVIRAL INC. (US) 2014-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170151253-A1 Compounds, Compositions, and Methods for Treating Alzheimer's Disease PSEN1, APP, PSEN2 NOX1 1944/4885MAPT 11/4885GAA 345/4885
US-20140315897-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ALZHEIMER'S DISEASE PSEN1, APP, PSEN2 NOX1 1944/4885MAPT 11/4885GAA 345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.